The endocannabinoid system and emotional processing: A pharmacological fMRI study with ∆9-tetrahydrocannabinol

European Neuropsychopharmacology

Volumn 23, Issue 12, 2013, Pages 1687-1697

  Bossong, Matthijs G ^a,b   van Hell, Hendrika H ^a   Jager, Gerry ^a,c   Kahn, René S ^a   Ramsey, Nick F ^a   Jansma, J Martijn ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Emotional processing; Endocannabinoid system; Functional MRI; 9 tetrahydrocannabinol (THC)

Indexed keywords

DRONABINOL; ENDOCANNABINOID; PLACEBO;

ADULT; ALERTNESS; AMYGDALOID NUCLEUS; ANXIETY; ARTICLE; BRAIN FUNCTION; CEREBELLUM VERMIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; ELECTROENCEPHALOGRAM; EMOTION; EMOTIONAL DISORDER; FACIAL EXPRESSION; FOLLOW UP; FRONTAL GYRUS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HEART RATE; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; MALE; MIDDLE FRONTAL GYRUS; NORMAL HUMAN; OCCIPITAL CORTEX; PARIETAL GYRUS; PERCEPTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; SUPPLEMENTARY MOTOR AREA; TASK PERFORMANCE; VISUAL ANALOG SCALE;

EMOTIONAL PROCESSING; ENDOCANNABINOID SYSTEM; FUNCTIONAL MRI; Δ9-TETRAHYDROCANNABINOL (THC);

ADOLESCENT; ADULT; BRAIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRONABINOL; EMOTIONS; ENDOCANNABINOIDS; FEAR; FEMALE; HEART RATE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MULTIVARIATE ANALYSIS; OXYGEN; PHOTIC STIMULATION; PSYCHOTROPIC DRUGS; VISUAL ANALOG SCALE; YOUNG ADULT;

EID: 84887615854     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.06.009     Document Type: Article

References (50)

1. Addy C., Rothenberg P., Li S., Majumdar A., Agrawal N., Li H., Zhong L., Yuan J., Maes A., Dunbar S., Cote J., Rosko K., van Dyck K., de Lepeleire I., de Hoon J., van Hecken A., Depre M., Knops A., Gottesdiener K., Stoch A., Wagner J. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J. Clin. Pharmacol. 2008, 48:734-744.
2. Adolphs R. Recognizing emotion from facial expressions: psychological and neurological mechanisms. Behav. Cogn. Neurosci. Rev. 2002, 1:21-62.
3. Ashton C.H. Pharmacology and effects of cannabis: a brief review. Br. J. Psychiatry 2001, 178:101-106.
4. Ashton C.H., Moore P.B. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr. Scand. 2011, 124:250-261.
5. Ballard M.E., Bedi G., de Wit H. Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images. J. Psychopharmacol. 2012, 26:1289-1298.
6. Bond A., Lader M. The use of analogue scales in rating subjective feelings. Br. J. Med. Psychol. 1974, 47:211-218.
7. Bossong M.G., Jager G., van Hell H.H., Zuurman L., Jansma J.M., Mehta M.A., van Gerven J.M., Kahn R.S., Ramsey N.F. Effects of delta9-tetrahydrocannabinol administration on human encoding and recall memory function: a pharmacological FMRI study. J. Cogn. Neurosci. 2012, 24:588-599.
8. Bossong M.G., Jansma J.M., van Hell H.H., Jager G., Oudman E., Saliasi E., Kahn R.S., Ramsey N.F. Effects of delta9-tetrahydrocannabinol on human working memory function. Biol. Psychiatry 2012, 71:693-699.
9. Bossong M.G., van Berckel B.N., Boellaard R., Zuurman L., Schuit R.C., Windhorst A.D., van Gerven J.M., Ramsey N.F., Lammertsma A.A., Kahn R.S. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009, 34:759-766.
10. Bowdle T.A., Radant A.D., Cowley D.S., Kharasch E.D., Strassman R.J., Roy-Byrne P.P. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 1998, 88:82-88.
11. Brett M., Anton J.-L., Valabregue R., Poline J.-B. Region of interest analysis using an SPM toolbox. Neuroimage 2002, 16:497. (Abstract).
12. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713.
13. Ekman P., Friesen W.V. Pictures of Facial Affect 1976, Consulting Psychologists Press, Palo Alto.
14. Eser D., Leicht G., Lutz J., Wenninger S., Kirsch V., Schule C., Karch S., Baghai T., Pogarell O., Born C., Rupprecht R., Mulert C. Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers. Hum. Brain Mapp. 2009, 30:511-522.
15. Friston K.J., Rotshtein P., Geng J.J., Sterzer P., Henson R.N. A critique of functional localisers. Neuroimage 2006, 30:1077-1087.
16. Fu C.H., Williams S.C., Brammer M.J., Suckling J., Kim J., Cleare A.J., Walsh N.D., Mitterschiffthaler M.T., Andrew C.M., Pich E.M., Bullmore E.T. Neural responses to happy facial expressions in major depression following antidepressant treatment. Am. J. Psychiatry 2007, 164:599-607.
17. Fusar-Poli P., Crippa J.A., Bhattacharyya S., Borgwardt S.J., Allen P., Martin-Santos R., Seal M., Surguladze S.A., O'Carrol C., Atakan Z., Zuardi A.W., McGuire P.K. Distinct effects of delta9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psychiatry 2009, 66:95-105.
18. Griebel G., Stemmelin J., Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 2005, 57:261-267.
19. Hariri A.R., Gorka A., Hyde L.W., Kimak M., Halder I., Ducci F., Ferrell R.E., Goldman D., Manuck S.B. Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function. Biol. Psychiatry 2009, 66:9-16.
20. Hariri A.R., Mattay V.S., Tessitore A., Kolachana B., Fera F., Goldman D., Egan M.F., Weinberger D.R. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002, 297:400-403.
21. Harmer C.J., Mackay C.E., Reid C.B., Cowen P.J., Goodwin G.M. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol. Psychiatry 2006, 59:816-820.
22. Harmer C.J., O'Sullivan U., Favaron E., Massey-Chase R., Ayres R., Reinecke A., Goodwin G.M., Cowen P.J. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am. J. Psychiatry 2009, 166:1178-1184.
23. Heifets B.D., Castillo P.E. Endocannabinoid signaling and long-term synaptic plasticity. Annu. Rev. Physiol. 2009, 71:283-306.
24. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 1991, 11:563-583.
25. Hill M.N., Hillard C.J., Bambico F.R., Patel S., Gorzalka B.B., Gobbi G. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol. Sci. 2009, 30:484-493.
26. Horder J., Browning M., Di Simplicio M., Cowen P.J., Harmer C.J. Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. J. Psychopharmacol. 2012, 26:125-132.
27. Horder J., Cowen P.J., Di Simplicio M., Browning M., Harmer C.J. Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. Psychopharmacology (Berl) 2009, 205:85-91.
28. Huestis M.A., Henningfield J.E., Cone E.J. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J. Anal. Toxicol. 1992, 16:276-282.
29. Iannetti G.D., Wise R.G. BOLD functional MRI in disease and pharmacological studies: room for improvement?. Magn. Reson. Imaging 2007, 25:978-988.
30. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 2003, 9:76-81.
31. Katona I., Rancz E.A., Acsady L., Ledent C., Mackie K., Hajos N., Freund T.F. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J. Neurosci. 2001, 21:9506-9518.
32. Lafenetre P., Chaouloff F., Marsicano G. The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. Pharmacol. Res. 2007, 56:367-381.
33. LeDoux J. The emotional brain, fear, and the amygdala. Cell. Mol. Neurobiol. 2003, 23:727-738.
34. Leppanen J.M. Emotional information processing in mood disorders: a review of behavioral and neuroimaging findings. Curr. Opin. Psychiatry 2006, 19:34-39.
35. Marco E.M., Perez-Alvarez L., Borcel E., Rubio M., Guaza C., Ambrosio E., File S.E., Viveros M.P. Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav. Pharmacol. 2004, 15:21-27.
36. Martin M., Ledent C., Parmentier M., Maldonado R., Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 2002, 159:379-387.
37. Millan M.J. The neurobiology and control of anxious states. Prog. Neurobiol. 2003, 70:83-244.
38. Murphy S.E., Norbury R., O'Sullivan U., Cowen P.J., Harmer C.J. Effect of a single dose of citalopram on amygdala response to emotional faces. Br. J. Psychiatry 2009, 194:535-540.
39. Neggers S.F., Hermans E.J., Ramsey N.F. Enhanced sensitivity with fast three-dimensional blood-oxygen-level-dependent functional MRI: comparison of SENSE-PRESTO and 2D-EPI at 3 T. NMR Biomed. 2008, 21:663-676.
40. Phan K.L., Angstadt M., Golden J., Onyewuenyi I., Popovska A., de Wit H. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J. Neurosci. 2008, 28:2313-2319.
41. Phillips M.L., Ladouceur C.D., Drevets W.C. A neural model of voluntary and automatic emotion regulation: implications for understanding the pathophysiology and neurodevelopment of bipolar disorder. Mol. Psychiatry 2008, 13:833-857.
42. Ramaekers J.G., Kauert G., van Ruitenbeek P., Theunissen E.L., Schneider E., Moeller M.R. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 2006, 31:2296-2303.
43. Ruehle S., Rey A.A., Remmers F., Lutz B. The endocannabinoid system in anxiety, fear memory and habituation. J. Psychopharmacol. 2012, 26:23-39.
44. Surguladze S., Brammer M.J., Keedwell P., Giampietro V., Young A.W., Travis M.J., Williams S.C., Phillips M.L. A differential pattern of neural response toward sad versus happy facial expressions in major depressive disorder. Biol. Psychiatry 2005, 57:201-209.
45. Surguladze S.A., Young A.W., Senior C., Brebion G., Travis M.J., Phillips M.L. Recognition accuracy and response bias to happy and sad facial expressions in patients with major depression. Neuropsychology 2004, 18:212-218.
46. Valjent E., Mitchell J.M., Besson M.J., Caboche J., Maldonado R. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br. J. Pharmacol. 2002, 135:564-578.
47. van Buuren M., Gladwin T.E., Zandbelt B.B., van den Heuvel M., Ramsey N.F., Kahn R.S., Vink M. Cardiorespiratory effects on default-mode network activity as measured with fMRI. Hum. Brain Mapp. 2009, 30:3031-3042.
48. van Hell H.H., Bossong M.G., Jager G., Kahn R.S., Ramsey N.F. Pharmacological Imaging of the Cannabinoid System (PhICS): towards understanding the role of the brain endocannabinoid system in human cognition. Int. J. Methods Psychiatr. Res. 2011, 20:10-27.
49. Zuurman L., Roy C., Schoemaker R.C., Hazekamp A., den Hartigh J., Bender J.C., Verpoorte R., Pinquier J.L., Cohen A.F., van Gerven J.M. Effect of intrapulmonary tetrahydrocannabinol administration in humans. J. Psychopharmacol. 2008, 22:707-716.
50. Zandbelt B.B., Gladwin T.E., Raemaekers M., van Buuren M., Neggers S.F., Kahn R.S., Ramsey N.F., Vink M. Within-subject variation in BOLD-fMRI signal changes across repeated measurements: quantification and implications for sample size. Neuroimage 2008, 42:196-206.